Wilmington Healthcare launches new platform to map the formulary landscape
February 4, 2021 |
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
4 February 2021
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Known as InFormulary XD, the solution uses a unique blend of data and real-world evidence to provide an objective view of the status of a product by indication, on formularies and within guidelines.
Users can drill down into NHS localities within defined territories to gain a more detailed view of how their products are performing in primary and secondary care and better understand the challenges where formularies overlap.
The tool’s grading system also enables companies to clearly see where their brands sit on formularies and benchmark their performance against the competition using a wealth of data and insight.
In addition, the platform can be used to connect formulary information with other data sources, such as key stakeholder databases and NHS documents associated with product indication and target formularies.
Armed with data and insights from the platform, pharma can create compelling go-to-market plans to improve or maintain market position, monitor progress and keep abreast of formulary changes at a glance.
Gareth Thomas, Managing Director of Wilmington Healthcare, said: “The formulary landscape is not only multi-layered and complex, it is also changing quickly as the NHS adopts the integrated care models outlined in the Long-term Plan. This means that formulary data must be regularly reviewed and updated.
“Our new InFormulary XD enables customers to build and maintain a comprehensive view of a product’s formulary status in the UK in real-time and benchmark its performance against the competition. This level of insight, combined with related stakeholder data, gives companies a real competitive advantage in everything from strategic planning, budgeting and resourcing to customer targeting.”
Ends
Notes to Editors
For more information, please contact: Andrew Baud and Catherine McNulty, Tala, +44 (0) 20 3397 3383 or +44 (0) 7775 715775, Email: andrew.baud@teamtala.com /catherine.mcnulty@teamtala.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Wilmington Healthcare makes new senior appointment
Healthcare intelligence provider Wilmington Healthcare, which incorporates Binley’s, NHiS, Wellards and HSJ, has promoted a longstanding employee, Shelley Jessop, to the role of Account Director.Shelley who has worked for Wilmington...
Wilmington Healthcare appoints new Account Director
Healthcare intelligence provider Wilmington Healthcare, which incorporates Binley’s, NHiS, Wellards and HSJ, has strengthened its salesforce with the appointment of Gareth Thurston as Account Director.
What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?
Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach
How will the NHS’s new medicines savings drive affect pharma?
Steve How and Sue Thomas, of Wilmington Healthcare, explore how pharma should engage with CCGs on prescribing saving targets
Launch of the HSJ Partnership Awards: a programme for inspirational organisations helping to transform the NHS
New Awards will recognise the many private sector organisations who partner with the NHS to deliver improved patient outcomes and cost-effective care
How can pharma help the NHS capitalise on its data?
Sue Thomas, Paul Midgley and Steve How, of Wilmington Healthcare, explain how pharma can work with the NHS to transform services
How can pharma engage with Accountable Care Systems?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain how pharma can add value across care pathways
New analysis shows emergency hospital admissions for people with Multiple Sclerosis continue to rise
Updated data published by Wilmington Healthcare and the MS Trust highlights need for more preventative care for MS patients
How will capitated budgets affect NHS spending?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP
Wilmington Healthcare launches new, integrated, digital channel to help pharma engage with the NHS
Healthcare intelligence provider Wilmington Healthcare has integrated its tools and resources online to help pharma navigate changes within the NHS, following the official launch of Sustainability and Transformation Plans (STPs)....